An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC

This is a single-center, open-label, single-arm phase II exploratory study evaluating a perioperative regimen of iparomlimab and tuvonralimab (QL1706; a bispecific PD-1/CTLA-4 antibody) combined with platinum-based chemotherapy in patients with resectable or potentially resectable stage IIB-IIIB non-small cell lung cancer (NSCLC) without actionable driver alterations. Approximately 30 eligible participants will receive three 21-day cycles of neoadjuvant QL1706 plus chemotherapy, followed by surgical resection if feasible. After surgery, participants will be followed regularly to assess patholo

Trial Details

NCT ID
NCT07452003
Phase
NA
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • QL1706 plus chemotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients are eligible for enrollment in this study only if they meet all of the following inclusion criteria and none of the exclusion criteria:
  • The subject voluntarily participates in the study, provides written informed consent, demonstrates good compliance, and is willing to cooperate wit…
  • Age ≥18 years at the time of signing the informed consent form; sex not restricted.
  • Histologically confirmed non-small cell lung cancer (NSCLC).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →